Search Result

Results for "

metastatic

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (3) ADC Cytotoxin (1) ADC Linker (2) Androgen Receptor (6) Antibiotic (5) Antibody-Drug Conjugates (ADCs) (1) Antifolate (2) Apoptosis (26) Arrestin (2) Aurora Kinase (1) Autophagy (6) Bacterial (4) c-Fms (1) c-Kit (1) c-Met/HGFR (1) Cathepsin (2) CCR (1) CD3 (2) CDK (4) Checkpoint Kinase (Chk) (1) Complement System (1) CTLA-4 (3) CX3CR1 (2) CXCR (4) Cytochrome P450 (1) Dengue virus (1) Discoidin Domain Receptor (1) DNA Alkylator/Crosslinker (1) DNA Stain (1) DNA-PK (2) DNA/RNA Synthesis (2) Drug Metabolite (1) Drug-Linker Conjugates for ADC (1) E1/E2/E3 Enzyme (3) EGFR (13) Endogenous Metabolite (7) Epigenetic Reader Domain (1) ERK (1) Estrogen Receptor/ERR (5) FGFR (2) Flavivirus (1) Glucosidase (1) Glutaminase (1) GSK-3 (1) Guanylate Cyclase (1) HDAC (4) Histone Methyltransferase (1) HPV (1) HSV (3) IAP (1) ICMT (1) IFNAR (1) Influenza Virus (1) Integrin (1) Isotope-Labeled Compounds (1) LAG-3 (1) Lipoxygenase (1) LPL Receptor (1) MAP3K (1) MDM-2/p53 (1) Microtubule/Tubulin (4) MMP (4) Necroptosis (1) NF-κB (4) Nucleoside Antimetabolite/Analog (3) Orthopoxvirus (1) PAI-1 (1) Parasite (1) PARP (1) PD-1/PD-L1 (8) Phosphatase (1) PI3K (1) PKC (1) PROTACs (1) Protease Activated Receptor (PAR) (1) PSMA (3) Raf (2) Ras (2) Reactive Oxygen Species (1) RET (1) ROCK (1) Src (1) STAT (1) TAM Receptor (3) TGF-beta/Smad (1) TGF-β Receptor (1) Thymidylate Synthase (1) TNF Receptor (1) Trk Receptor (1) TrxR (1) VD/VDR (1) VEGFR (4) VSV (1) Wnt (4) β-catenin (1)
By Research Areas:	Cancer (159) Cardiovascular Disease (3) Endocrinology (8) Infection (6) Inflammation/Immunology (15) Metabolic Disease (2) Neurological Disease (6)

By Targets:

ADC Antibody (3)

ADC Cytotoxin (1)

ADC Linker (2)

Androgen Receptor (6)

Antibiotic (5)

Antibody-Drug Conjugates (ADCs) (1)

Antifolate (2)

Apoptosis (26)

Arrestin (2)

Aurora Kinase (1)

Autophagy (6)

Bacterial (4)

c-Fms (1)

c-Kit (1)

c-Met/HGFR (1)

Cathepsin (2)

CCR (1)

CD3 (2)

CDK (4)

Checkpoint Kinase (Chk) (1)

Complement System (1)

CTLA-4 (3)

CX3CR1 (2)

CXCR (4)

Cytochrome P450 (1)

Dengue virus (1)

Discoidin Domain Receptor (1)

DNA Alkylator/Crosslinker (1)

DNA Stain (1)

DNA-PK (2)

DNA/RNA Synthesis (2)

Drug Metabolite (1)

Drug-Linker Conjugates for ADC (1)

E1/E2/E3 Enzyme (3)

EGFR (13)

Endogenous Metabolite (7)

Epigenetic Reader Domain (1)

ERK (1)

Estrogen Receptor/ERR (5)

FGFR (2)

Flavivirus (1)

Glucosidase (1)

Glutaminase (1)

GSK-3 (1)

Guanylate Cyclase (1)

HDAC (4)

Histone Methyltransferase (1)

HPV (1)

HSV (3)

IAP (1)

ICMT (1)

IFNAR (1)

Influenza Virus (1)

Integrin (1)

Isotope-Labeled Compounds (1)

LAG-3 (1)

Lipoxygenase (1)

LPL Receptor (1)

MAP3K (1)

MDM-2/p53 (1)

Microtubule/Tubulin (4)

MMP (4)

Necroptosis (1)

NF-κB (4)

Nucleoside Antimetabolite/Analog (3)

Orthopoxvirus (1)

PAI-1 (1)

Parasite (1)

PARP (1)

PD-1/PD-L1 (8)

Phosphatase (1)

PI3K (1)

PKC (1)

PROTACs (1)

Protease Activated Receptor (PAR) (1)

PSMA (3)

Raf (2)

Ras (2)

Reactive Oxygen Species (1)

RET (1)

ROCK (1)

Src (1)

STAT (1)

TAM Receptor (3)

TGF-beta/Smad (1)

TGF-β Receptor (1)

Thymidylate Synthase (1)

TNF Receptor (1)

Trk Receptor (1)

TrxR (1)

VD/VDR (1)

VEGFR (4)

VSV (1)

Wnt (4)

β-catenin (1)

By Research Areas:

Cancer (159)

Cardiovascular Disease (3)

Endocrinology (8)

Infection (6)

Inflammation/Immunology (15)

Metabolic Disease (2)

Neurological Disease (6)

161

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99933

Eftilagimod alfa IMP321; LAG-3Ig	LAG-3	Cancer
Eftilagimod alfa (IMP321) is a recombinant LAG-3Ig fusion protein that binds to MHC class II. Eftilagimod alfa mediates antigen-presenting cell (APC) activation followed by CD8 T-cell activation. Eftilagimod alfa can be used for metastatic melanoma and metastatic breast carcinoma research .

HY-13442

Eribulin 1 Publications Verification B1939; E7389; ER-086526	Microtubule/Tubulin Apoptosis ADC Cytotoxin	Cancer
Eribulin (E7389) is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.

HY-13442A

Eribulin mesylate 1 Publications Verification B1939 mesylate; E7389 mesylate; ER-086526 mesylate	Microtubule/Tubulin Apoptosis	Cancer
Eribulin (E7389) mesylate is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin mesylate inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.

HY-149949

Anticancer agent 105	Apoptosis	Cancer
Anticancer agent 105 is a compound based on thienopyrimidine scaffold, with with good safety and anticancer properties. Anticancer agent 105 shows selective toxicity towards melanoma cancer, and induces apoptosis. And Anticancer agent 105 significantly inhibits the metastatic nodules, even in pulmonary metastatic melanoma mouse model .

HY-149950

Anticancer agent 106	Apoptosis	Cancer
Anticancer agent 106 (compound 10ic) is an anticancer agent that induces apoptosis in B16-F10 melanoma cells. Anticancer agent 106 also potently inhibits metastatic nodules in a mouse model of lung metastatic melanoma. Anticancer agent 106 can be used in the study of cancer, especially lung metastatic melanoma .

HY-119001

BKM1644	Others	Cancer
BKM1644, an acyl-tyrosine bisphosphonate amide derivative, exhibits potent anti-cancer activity. BKM1644 effectively inhibits the proliferation of metastatic, castration-resistant prostate cance (mCRPC) cells. BKM1644 sensitizes mCRPC cells to Docetaxel (HY-B0011) and retards the bone metastatic growth of prostate cance .

HY-P99384

Vofatamab B-701; MFGR-1877S; RG-7444	FGFR	Cancer
Vofatamab (B-701) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC) .

HY-P9901

Ipilimumab 3 Publications Verification MDX-010; BMS-734016	CTLA-4	Cancer
Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies .

HY-139376

FGFR1 inhibitor-2	FGFR	Cancer
FGFR1 inhibitor-2 is a FGFR1 inhibitor (IC₅₀ is 4.55 μM in MDA-MB-231 cells). FGFR1 inhibitor-2 can be used for the research of metastatic triple-negative breast cancer .

HY-144204

Estrogen receptor antagonist 5	Estrogen Receptor/ERR	Endocrinology Cancer
Estrogen receptor antagonist 5 is a potent antagonist of Estrogen receptor. The estrogen receptor is a ligand-activated transcriptional regulatory protein that mediates induction of a variety of biological effects through its interaction with endogenous estrogens. Estrogen receptor antagonist 5 has the potential for the research of metastatic disease (extracted from patent WO2017174757A1, compound 165) .

HY-144206

Estrogen receptor antagonist 6	Estrogen Receptor/ERR	Endocrinology
Estrogen receptor antagonist 6 is a potent antagonist of Estrogen receptor. The estrogen receptor is a ligand-activated transcriptional regulatory protein that mediates induction of a variety of biological effects through its interaction with endogenous estrogens. Estrogen receptor antagonist 6 has the potential for the research of metastatic disease (extracted from patent WO2017174757A1, compound 166) .

HY-P99045

Sacituzumab	ADC Antibody	Cancer
Sacituzumab is a humanized IgG1 monoclonal antibody for anti-trophoblast cell-surface antigen 2 (anti-Trop-2). Sacituzumab has the potential for metastatic triple-negative breast cancer research .

HY-P99117

Cadonilimab AK104	PD-1/PD-L1	Cancer
Cadonilimab (AK104) is a targeting PD1/CTLA4 IgG1 scaffold Fc-engineered humanized antibody. Cadonilimab can be used for researching metastatic cervical cancer .

HY-127009

Levoleucovorin Levofolinic acid; Levofolene	Endogenous Metabolite	Cancer
Levoleucovorin (Levofolinic acid) is the pharmacologically active levoisomer of racemic leucovorin. Levoleucovorin can be used as a rescue agent after high-dose Methotrexate (HY-14519) therapy, and in combination with fluorouracil for the research of advanced metastatic colorectal cancer .

HY-B0078B

Dacarbazine hydrochloride Imidazole Carboxamide hydrochloride	Antibiotic	Cancer
Dacarbazine hydrochloride is a cell cycle nonspecific antineoplastic alkylating agent. Dacarbazine hydrochloride inhibits T and B lymphoblastic response, with IC₅₀ values of 50 and 10 μg/mL, respectively. Dacarbazine hydrochloride can be used for the research of metastatic malignant melanoma .

HY-P9918

Tremelimumab Ticilimumab; CP-675206	CTLA-4	Inflammation/Immunology Cancer
Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research .

HY-P99476

ABP 215	VEGFR	Cancer
ABP 215 (Bevacizumab-awwb), a Bevacizumab (Bevacizumab (HY-P9906)) biosimilar, is a humanized IgG1 monoclonal antibody targeting VEGFA (VEGFR). ABP 215 has anticancer effects, and can be used metastatic colorectal cancer (mCRC) research .

HY-P99030

Margetuximab	EGFR	Cancer
Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC₅₀ value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer .

HY-W181530

NCT02	CDK	Cancer
NCT02 is a cyclin K degrader. NCT02 induces ubiquitination of cyclin K (CCNK) and proteasomal degradation of CCNK and its complex partner CDK12. NCT02 has the potential for the research of metastatic colorectal cancer (CRC) .

HY-16189

Elliptinium acetate NSC 264137; Celiptium	DNA Stain	Cancer
Elliptinium acetate (NSC 264137) is a DNA intercalating agent that is highly cytotoxic to L1 210 cells and covalently binds to nucleic acids from L1210 cells. Elliptinium acetate can be used in cancer research, particularly in metastatic breast cancer .

HY-158102

ORIC-944	Others	Cancer
ORIC-944 is a selective, orally active, allosteric inhibitor targeting the EED subunit of polycomb repressive complex 2 (PRC2). ORIC-944 is synergistic with androgen receptor pathway inhibitors (ARPIs) for the study of metastatic prostate cancer.

HY-A0061

Trifluridine 1 Publications Verification Trifluorothymidine; 5-Trifluorothymidine; TFT	Thymidylate Synthase HSV Nucleoside Antimetabolite/Analog Orthopoxvirus DNA/RNA Synthesis Apoptosis Autophagy	Cancer
Trifluridine (Trifluorothymidine) is an irreversible and orally active thymidylate synthase inhibitor, and thereby suppressing DNA synthesis. Trifluridine is an antiviral molecule used for research of HSV, rhabdovirus and orthopoxvirus infection. Trifluridine induces cell apoptosis and autophagy. Trifluridine is also an anticancer agent used in studies of metastatic colorectal cancer, gastrointestinal tumors .

HY-150639

Everafenib	Raf	Cancer
Everafenib is a potent and blood-brain barrier (BBB) penetrant BRAF inhibitor, also inhibits MAPK signaling. Everafenib has inhibitory activity against a panel of ^V600EBRAF melanoma cell lines with IC₅₀ values of 2-10 nM, which is better than Dabrafenib (HY-14660) and Vemurafenib (HY-12057). Everafenib has efficacy in an intracranial mouse model of metastatic melanoma .

HY-136174

RBN-2397 5+ Cited Publications	PARP	Cancer
RBN-2397 is a potent, accross species and orally active NAD ⁺ competitive inhibitor of PARP7 (IC₅₀<3 nM). RBN-2397 selectively binds to PARP7 (K_d=0.001 μM) and restores IFN signaling. RBN-2397 has the potential for the study of advanced or metastatic solid tumors .

HY-B0078A

Dacarbazine citrate Imidazole Carboxamide citrate	Apoptosis Antibiotic	Cancer
Dacarbazine citrate is a cell cycle nonspecific antineoplastic alkylating agent. Dacarbazine citrate inhibits T and B lymphoblastic response, with IC₅₀ values of 50 and 10 μg/mL, respectively. Dacarbazine Citrate can be used for the research of apoptosis and various cancers such as metastatic malignant melanoma .

HY-118762

KGP94	Cathepsin	Cancer
KGP94 is a selective inhibitor of cathepsin L with an IC₅₀ of 189 nM . KGP94 inhibits migration and invasion of metastatic carcinoma and shows low cytotoxicity (GI₅₀=26.9 µM) against various human cell lines .

HY-136244

PF-06952229 1 Publications Verification	TGF-β Receptor	Cancer
PF-06952229 is a potent, selective and orally active TGFbR1 inhibitor. PF-06952229 specifically binds to TGFbR1 and prevents TGFbR1-mediated signal transduction. PF-06952229 is a promising antineoplastic agent for the study solid tumors, especifically metastatic breast cancer .

HY-120118

Metarrestin ML246	DNA/RNA Synthesis	Cancer
Metarrestin (ML246) is an orally active, first-in-class and specific perinucleolar compartment inhibitor. Metarrestin disrupts the nucleolar structure and inhibits RNA polymerase (Pol) I transcription, at least in part by interacting with the translation elongation factor eEF1A2. Metarrestin blocks metastatic development and extends survival in mouse cancer models .

HY-158125

PSMA binder-2	PSMA	Cancer
PSMA binder-2 is a ligand for PSMA and can be used to synthesize Ac-PSMA-trillium. Ac-PSMA-trillium is a suitable PSMA-targeting compound with improved PSMA binding properties and pharmacokinetic properties. PSMA ligands have different biological applications after being modified with different radioactive isotopes. If labeled with ¹¹¹In, it can be used as DOTA chelating agent and imaging agent. Or labeled with ²²⁵Ac as a Macropa chelator for targeted radionuclide therapy (TRT) in the study of metastatic castration-resistant prostate cancer (mCRPC) .

HY-158119

Ac-PSMA-trillium	PSMA	Cancer
Ac-PSMA-trillium is a PSMA targeting compound, consisting of a PSMA targeting molecule (PSMA binder), a Macropa chelating molecule, and a group that regulates pharmacokinetics (PK modifier). Ac-PSMA-trillium is a non-radioactive form of Actinium-225-PSMA-Trillium (BAY 3563254) with improved PSMA targeting and pharmacokinetic properties. PSMA-trillium can bind Ac through the Macropa chelating molecule, or the radioactive isotope ²²⁵Actinium. Actinium-225-PSMA-Trillium is a potent inhibitor of metastatic castration-resistant prostate cancer (mCRPC) .

HY-16215

Mipsagargin G-202	Drug-Linker Conjugates for ADC	Cancer
Mipsagargin (G-202) is a novel thapsigargin-based targeted proagent consisting of a prostate-specific membrane antigen (PSMA)-specific peptide coupled to an analog of the potent sarcoplasmic/endoplasmic reticulum calcium adenosine triphosphatase (SERCA) pump inhibitor Thapsigargin (HY-13433). Mipsagargin is activated by PSMA-mediated cleavage of an inert masking peptide. Mipsagargin has the potential for refractory, advanced or metastatic solid tumours research .

HY-158123

PSMA binder-1	PSMA	Cancer
PSMA binder-1 is a ligand for PSMA and can be used to synthesize Ac-PSMA-trillium. Ac-PSMA-trillium is a suitable PSMA-targeting compound with improved PSMA binding properties and pharmacokinetic properties. PSMA ligands have different biological applications after being modified with different radioactive isotopes. If labeled with ¹¹¹In, it can be used as DOTA chelating agent and imaging agent. Or it can be labeled with ²²⁵Ac (to obtain Actinium-225-PSMA-Trillium (BAY 3563254)), which has a radioactive killing effect; it can be used as a Macropa chelator for targeted radionuclide therapy (TRT) , has a strong inhibitory effect on metastatic castration-resistant prostate cancer (mCRPC) .

HY-N3360

Lupalbigenin

Apoptosis Cancer

Lupalbigenin is a natural compound with anti-metastatic and pro-apoptotic effects .

Lupalbigenin	Apoptosis	Cancer
Lupalbigenin is a natural compound with anti-metastatic and pro-apoptotic effects .

HY-P99437

Anbenitamab KN-026	EGFR	Cancer
Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting the extracellular domains II and IV of the human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathway. The IgG1 Fc fragment of Anbenitamab binds FcRγIIIa mediates potent antibody dependent cell-mediated cytotoxicity (ADCC) and inhibits tumor cell proliferation. Anbenitamab has the potential for HER2-positive metastatic breast cancer (MBC) research .

HY-158122

Lys(CO-C3-p-I-Ph)-O-tBu	DNA-PK	Cancer
Lys(CO-C3-p-I-Ph)-O-tBu is a pharmacokinetic modifier (PK modifier) that can improve the PK properties of PSMA ligand molecules. Lys(CO-C3-p-I-Ph)-O-tBu can increase the residence time of PSMA ligand in plasma by increasing its binding capacity to albumin. Lys(CO-C3-p-I-Ph)-O-tBu also reduces salivary gland absorption, possibly extending the half-life of the active compound. Ac-PSMA-trillium is a suitable PSMA-targeting compound that has different biological applications after modification with different radioactive isotopes. If labeled with ¹¹¹In, it can be used as DOTA chelating agent and imaging agent. Or labeled with ²²⁵Ac as a Macropa chelator for targeted radionuclide therapy (TRT) in the study of metastatic castration-resistant prostate cancer (mCRPC) .

HY-162379

Anticancer agent 200

Others Cancer

Anticancer agent 200 (6d) is a potential noncovalent anticancer inhibitor and an anti-metastatic agent .

Anticancer agent 200	Others	Cancer
Anticancer agent 200 (6d) is a potential noncovalent anticancer inhibitor and an anti-metastatic agent .

HY-16173

Mipicoledine DM-CHOC-PEN	DNA Alkylator/Crosslinker	Neurological Disease Cancer
Mipicoledine is a potential neuro-alkylating agent for study of glioblastoma and metastatic cancers involving the central nervous system .

HY-158118

Lys(CO-C3-p-I-Ph)-OMe	DNA-PK	Cancer
Lys(CO-C3-p-I-Ph)-OMe is a pharmacokinetic modifier (PK modifier) that can improve the PK properties of PSMA ligand molecules (such as Ac-PSMA-trillium). Lys(CO-C3-p-I-Ph)-OMe can increase the residence time of Ac-PSMA-trillium in plasma by increasing its binding capacity to albumin. Lys(CO-C3-p-I-Ph)-OMe also reduces salivary gland absorption of Ac-PSMA-trillium, potentially extending its half-life. Ac-PSMA-trillium is a suitable PSMA-targeting compound that has different biological applications after modification with different radioactive isotopes. If labeled with ¹¹¹In, it can be used as DOTA chelating agent and imaging agent. Or labeled with ²²⁵Ac as a Macropa chelator for targeted radionuclide therapy (TRT) in the study of metastatic castration-resistant prostate cancer (mCRPC) .

HY-P99463

Batiraxcept AVB-S6-500	TAM Receptor	Cancer
Batiraxcept (AVB-S6-500) is a highly potent and specific AXL inhibitor, a recombinant fusion protein dimer containing the extracellular domain of human AXLM and human immunoglobulin G1 heavy chain (Fc). Batiraxcept binds to GAS6 and inhibits the interaction of GAS6 with AXL, thereby substantially reducing AXL signaled invasion and migration of highly metastatic cells in vitro and inhibiting metastatic disease in nonclinical models of aggressive human cancers. Batiraxcept is available for studies in advanced or metastatic clear cell renal cell carcinoma (ccRCC) and platinum sensitive recurrent ovarian cancer .

HY-P9974

Vantictumab OMP-18R5	Wnt	Cancer
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab is being studied against cancers such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma .

HY-P9912A

Pertuzumab (PBS)

EGFR Cancer

Pertuzumab (PBS), a humanized monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.
HY-126899

TPI-287

Microtubule/Tubulin Cancer

TPI-287, a blood-brain barrier-permeable microtubule stabilizer, can significantly reduce metastatic colonization of breast cancer in the brain .

Pertuzumab (PBS)	EGFR	Cancer
Pertuzumab (PBS), a humanized monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

TPI-287	Microtubule/Tubulin	Cancer
TPI-287, a blood-brain barrier-permeable microtubule stabilizer, can significantly reduce metastatic colonization of breast cancer in the brain .

HY-P9912

Pertuzumab 3 Publications Verification	EGFR	Cancer
Pertuzumab, a humanized IgG1 monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

HY-111578

BDP-13176 1 Publications Verification	Others	Cancer
BDP-13176 is a potent fascin 1 inhibitor, with a K_d of 90 nM and an IC₅₀ of 240 nM. BDP-13176 has potential as an anti-metastatic agent .

HY-136718

CLEFMA	Apoptosis	Cancer
CLEFMA is a curcuminoid with antitumor activity. CLEFMA inhibits tumor growth is associated with NF-κB-regulated anti-inflammatory and anti-metastatic effects .

HY-111172

Inotilone	MMP NF-κB	Cancer
Inotilone is an inhibitor of matrix metalloproteinase MMP-2 and MMP-9, to against metastatic in lung cancer cells. Inotilone enhances the activity of the antioxidant enzymes to support its anti-metastatic activity. Inotilone also inhibits IκBα phosphorylation and NFκB p65 nuclear translocation, involving in FAK, PI3K/AKT, MAPKs and NFκB pathways .

HY-149951

Anticancer agent 107	Others	Cancer
Anticancer agent 107(Compd 11jc) has significant antitumor activity and can be used as an anticancer agent in the study of pulmonary metastatic melanoma .

HY-124674

CCT365623

Lipoxygenase Cancer

CCT365623 is a potent and orally active LOX inhibitor with an IC₅₀ of 0.9 μM. CCT365623 has potent anti-metastatic efficacy in vivo .

HY-124939

ND-322 hydrochloride	MMP	Cancer
ND-322 hydrochloride is a potent and selective water-soluble gelatinase inhibitor. ND-322 hydrochloride reduces melanoma tumor growth and delays metastatic dissemination .

HY-P9903

Nivolumab 15+ Cited Publications BMS-936558; ONO-4538; MDX-1106	PD-1/PD-L1	Cancer
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

Cat. No.	Product Name	Target	Research Area

HY-P4116

pH-Low Insertion Peptide pHLIP	Peptides	Others
pH-Low Insertion Peptide (pHLIP) used as a specific ligand to target the tumor acidic microenvironment for tumors at early and metastatic stages .

HY-P0122B

iRGD peptide 1 TFA	Peptides	Cancer
iRGD peptide 1 TFA is the prototypic tumor-specific tissue-penetrating peptide, which delivers agents deep into extravascular tumor tissue. iRGD peptide 1 TFA has anti-metastatic activity .

HY-16215

Mipsagargin G-202	Drug-Linker Conjugates for ADC	Cancer
Mipsagargin (G-202) is a novel thapsigargin-based targeted proagent consisting of a prostate-specific membrane antigen (PSMA)-specific peptide coupled to an analog of the potent sarcoplasmic/endoplasmic reticulum calcium adenosine triphosphatase (SERCA) pump inhibitor Thapsigargin (HY-13433). Mipsagargin is activated by PSMA-mediated cleavage of an inert masking peptide. Mipsagargin has the potential for refractory, advanced or metastatic solid tumours research .

HY-P4102

Cyclic PSAP peptide	Peptides	Cancer
Cyclic PSAP peptide is a cyclic pentapeptide (DWLPK). Cyclic PSAP peptide exhibits agent-like properties and could inhibit metastatic spread and restrain tumor development in general in vivo .

HY-P3099

Uroguanylin (human)	Guanylate Cyclase	Cancer
Uroguanylin (human) is a natural ligand for the Guanylyl Cyclase (GCC) receptor expressed in metastatic colorectal cancer tumors. Uroguanylin (human) has anti-tumor actions in an animal model for human colon cancer .

HY-P4340

Arg-Arg-AMC	Cathepsin	Cancer
Arg-Arg-AMC is a highly selective substrate of Cathepsin B. Arg-Arg-AMC can be used to cathepsin B activity assay in cancer cells, while cathepsin B is assocaited with cell invasive and metastatic phenotype in numerous types of cancer .

HY-P3342

[D-Leu-4]-OB3	PD-1/PD-L1 Apoptosis	Inflammation/Immunology
[D-Leu-4]-OB3 inhibits expressions of pro-inflammatory, proliferative and metastatic genes and PD-L1 expression. [D-Leu-4]-OB3 stimulates expression of pro-apoptotic genes .

HY-P1416

Foxy-5	Wnt	Cancer
Foxy-5, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model .

HY-P1416A

Foxy-5 TFA 3 Publications Verification	Wnt	Cancer
Foxy-5 TFA, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 TFA triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 TFA effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model .

HY-107146

PZ-128 P1pal-7	Protease Activated Receptor (PAR)	Cardiovascular Disease Cancer
PZ-128 (P1pal-7), a cell-penetrating lipopeptide pepducin, is a first-in-class, specific and reversible protease-activated receptor-1 (PAR1) antagonist. PZ-128 targets the cytoplasmic surface of PAR1 and interrupts signaling to internally-located G (PAR1-G) proteins. PZ-128 has antiplatelet, anti-metastatic, anti-angiogenic and anticancer effects .

HY-P1682A

Balixafortide TFA 1 Publications Verification POL6326 TFA	CXCR Arrestin	Cancer
Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC₅₀ < 10 nM. Balixafortide TFA shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide TFA blocks β-arrestin recruitment and calcium flux with IC₅₀s < 10 nM. Balixafortide TFA is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects .

HY-P1682

Balixafortide POL6326	CXCR Arrestin	Cancer
Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC₅₀ < 10 nM. Balixafortide shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide blocks β-arrestin recruitment and calcium flux with IC₅₀s < 10 nM. Balixafortide is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects .

Cat. No.	Product Name	Target	Research Area

HY-P99933

Eftilagimod alfa IMP321; LAG-3Ig	LAG-3	Cancer
Eftilagimod alfa (IMP321) is a recombinant LAG-3Ig fusion protein that binds to MHC class II. Eftilagimod alfa mediates antigen-presenting cell (APC) activation followed by CD8 T-cell activation. Eftilagimod alfa can be used for metastatic melanoma and metastatic breast carcinoma research .

HY-P99049

Sotigalimab	Inhibitory Antibodies	Inflammation/Immunology Cancer
Sotigalimab, a CD40 agonistic monoclonal antibody, can be used for the research of metastatic pancreatic adenocarcinoma .

HY-P99384

Vofatamab B-701; MFGR-1877S; RG-7444	FGFR	Cancer
Vofatamab (B-701) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC) .

HY-P9901

Ipilimumab 3 Publications Verification MDX-010; BMS-734016	CTLA-4	Cancer
Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies .

HY-P99045

Sacituzumab	ADC Antibody	Cancer
Sacituzumab is a humanized IgG1 monoclonal antibody for anti-trophoblast cell-surface antigen 2 (anti-Trop-2). Sacituzumab has the potential for metastatic triple-negative breast cancer research .

HY-P99117

Cadonilimab AK104	PD-1/PD-L1	Cancer
Cadonilimab (AK104) is a targeting PD1/CTLA4 IgG1 scaffold Fc-engineered humanized antibody. Cadonilimab can be used for researching metastatic cervical cancer .

HY-P9918

Tremelimumab Ticilimumab; CP-675206	CTLA-4	Inflammation/Immunology Cancer
Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research .

HY-P99476

ABP 215	VEGFR	Cancer
ABP 215 (Bevacizumab-awwb), a Bevacizumab (Bevacizumab (HY-P9906)) biosimilar, is a humanized IgG1 monoclonal antibody targeting VEGFA (VEGFR). ABP 215 has anticancer effects, and can be used metastatic colorectal cancer (mCRC) research .

HY-P99030

Margetuximab	EGFR	Cancer
Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC₅₀ value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer .

HY-P99437

Anbenitamab KN-026	EGFR	Cancer
Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting the extracellular domains II and IV of the human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathway. The IgG1 Fc fragment of Anbenitamab binds FcRγIIIa mediates potent antibody dependent cell-mediated cytotoxicity (ADCC) and inhibits tumor cell proliferation. Anbenitamab has the potential for HER2-positive metastatic breast cancer (MBC) research .

HY-P99463

Batiraxcept AVB-S6-500	TAM Receptor	Cancer
Batiraxcept (AVB-S6-500) is a highly potent and specific AXL inhibitor, a recombinant fusion protein dimer containing the extracellular domain of human AXLM and human immunoglobulin G1 heavy chain (Fc). Batiraxcept binds to GAS6 and inhibits the interaction of GAS6 with AXL, thereby substantially reducing AXL signaled invasion and migration of highly metastatic cells in vitro and inhibiting metastatic disease in nonclinical models of aggressive human cancers. Batiraxcept is available for studies in advanced or metastatic clear cell renal cell carcinoma (ccRCC) and platinum sensitive recurrent ovarian cancer .

HY-P9974

Vantictumab OMP-18R5	Wnt	Cancer
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab is being studied against cancers such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma .

HY-P9912A

Pertuzumab (PBS)

EGFR Cancer

Pertuzumab (PBS), a humanized monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

HY-P9912

Pertuzumab 3 Publications Verification	EGFR	Cancer
Pertuzumab, a humanized IgG1 monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

HY-P9903

Nivolumab 15+ Cited Publications BMS-936558; ONO-4538; MDX-1106	PD-1/PD-L1	Cancer
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

HY-P99318

Sonepcizumab LT 1009; Anti-Human S1P Recombinant Antibody	LPL Receptor	Cancer
Sonepcizumab (LT 1009) is a fully human anti-S1P monoclonal antibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC) .

HY-P99812

Ragifilimab INCAGN-1876	TNF Receptor	Cancer
Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody targeting the glucocorticoid-induced TNFR-related protein (GITR). Ragifilimab can be used for advanced or metastatic solid tumors research .

HY-P99100

Visugromab

CTL-002
PD-1/PD-L1 Cancer

Visugromab is aGDF-15 neutralizing IgG4 mAb. Visugromab exhibits potent effecicacy in PD-1/PD-L1 relapsed/refractory metastatic solid tumors .

HY-P9903A

Nivolumab (anti-PD-1) 15+ Cited Publications	PD-1/PD-L1	Cancer
Nivolumab (anti-PD-1) is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer .

HY-P99461

Barecetamab ISU-104	EGFR	Cancer
Barecetamab (ISU-104) is a fully human anti-ErbB3 monoclonal antibody. Barecetamab can be used for the research of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) .

HY-P9907

Trastuzumab Maximum Cited Publications 21 Publications Verification Anti-Human HER2, Humanized Antibody	EGFR ADC Antibody	Cancer
Trastuzumab is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

HY-P9907A

Trastuzumab (anti-HER2) Maximum Cited Publications 21 Publications Verification Anti-Human HER2, Humanized Antibody (PBS)	ADC Antibody EGFR	Cancer
Trastuzumab (PBS) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (PBS) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

HY-P99544

Tagitanlimab HBM-9167; KL-A167	PD-1/PD-L1	Cancer
Tagitanlimab (HBM-9167) is a humanized anti-PD-L1 antibody (IgG1κ type). Tagitanlimab selectively blocks the interaction of PD-L1 and PD-1. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC) .

HY-P99802

Pasotuxizumab BAY 2010112; AMG 212	CD3	Cancer
Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with K_Ds of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .

HY-P99714

Lorigerlimab MGD019	PD-1/PD-L1 CTLA-4	Cancer
Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .

HY-108798

Ziv-aflibercept	VEGFR	Cardiovascular Disease Cancer
Ziv-aflibercept is a soluble inhibitor of vascular endothelial growth factor (VEGF). Ziv-aflibercept is an adaptive variant of Aflibercept (HY-108801), Ziv-aflibercept has a low PH value and high osmotic pressure when compared to Aflibercept. Ziv-aflibercept has potential applications in metastatic colorectal carcinoma and retinal diseases .

HY-P99594

Socazolimab ZKAB001; STI-1014; STI-A1014	PD-1/PD-L1	Cancer
Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma .

HY-P99406

Petosemtamab MCLA 158	EGFR	Cancer
Petosemtamab (MCLA 158) is an anti- EGFR (K_d: 0.22 nM) and anti-LGR5 (K_d: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .

HY-P99386

Vesencumab MNRP-1685A	Complement System	Cancer
Vesencumab (MNRP-1685A) is IG1 antibody against neuropilin-1 (NRP-1). Vesencumab binds to NRP-1 and prevents the subsequent coupling of NRP-1 to VEGFR-2. Vesencumab has anti-angiogenic and anti-neoplastic activities. Vesencumab can be used in the research of metastatic solid tumors, including ovarian cancer .

HY-P99708

Livmoniplimab ABBV-151; ARGX-115	TGF-beta/Smad	Cancer
Livmoniplimab (ABBV-151; ARGX-115) is a potent, humanized monoclonal antibody against the LRRC32 (GARP)/TGFβ1 complex. Livmoniplimab blocks LRRC32-mediated latent TGFβ1 activation and release. Livmoniplimab has potential in cancer research as a single anticancer agent or in combination with an anti-PD-1 mAb to inhibit locally advanced or metastatic solid tumors (NCT03821935) .

HY-P99630

Gancotamab MM-302	EGFR	Cancer
Gancotamab (MM-302) is a HER2-targeted antibody-liposomal Doxorubicin conjugate with antitumor activity. Gancotamab encapsulates Doxorubicin to facilitate its delivery to HER2-overexpressing tumor cells .

HY-P99011

Cibisatamab	CD3	Cancer
Cibisatamab (CEA-TCB), a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab (CEA-TCB) triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab (CEA-TCB) can be used for colorectal cancer research .

HY-P99215

Parsatuzumab Anti-EGFL7; RG 7414	VEGFR	Cancer
Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition .

HY-P99032

Monalizumab 1 Publications Verification IPH2201	Checkpoint Kinase (Chk) IFNAR	Inflammation/Immunology Cancer
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113462

α-Carotene	Structural Classification Classification of Application Fields Daucus carota Linn. var. sativa Hoffm. Source classification Plants Food Research Other Terpenoids Microorganisms Terpenoids Pigments Umbelliferae Disease Research Fields Cancer	Others
α-Carotene, a precursor of vitamin A, is used as an anti-metastatic agent or as an adjuvant for anti-cancer agents. α-Carotene is isolated from yellow-orange and dark-green vegetables .

HY-N6797

Meleagrin	Infection Alkaloids Microorganisms Classification of Application Fields Source classification Disease Research Fields Indole Alkaloids	Bacterial c-Met/HGFR Antibiotic
Meleagrin is a roquefortine C-derived alkaloid produced by fungi of the genus Penicillium and has antimicrobial and anti-proliferative activities. Meleagrin is a class of FabI inhibitor. Meleagrin is a lead c-Met inhibitory entity useful for the control of c-Met-dependent metastatic and invasive breast malignancies .

HY-17462

Adrenosterone (+)-Adrenosterone	Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Endocrinology Steroids	Androgen Receptor Endogenous Metabolite
Adrenosterone ((+)-Adrenosterone) is a competitive hydroxysteroid (11-beta) dehydrogenase 1 (HSD11β1) inhibitor. Adrenosterone is a steroid hormone with weak androgenic effect. Adrenosterone is a dietary supplement that can decrease fat and increase muscle mass. Adrenosterone acts as a suppressor of metastatic progression of human cancer cells .

HY-N3360

Lupalbigenin	Structural Classification Flavonoids Leguminosae Source classification Plants Derris taiwaniana (Hayata) Z. Q. Song Isoflavones	Apoptosis
Lupalbigenin is a natural compound with anti-metastatic and pro-apoptotic effects .

HY-109051C

Arfolitixorin sulfate	Structural Classification Alkaloids Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite
Arfolitixorin sulfate is a potent 5-Fluorouracil (5-FU) moderator. Arfolitixorin sulfate is an immediately active form of Folate, [6R]-5,10-methylenetetrahydrofolate ([6R]-MTHF). Arfolitixorin sulfate is potent for the research of metastatic colorectal cancer .

HY-N2022

Castanospermine 2 Publications Verification	Alkaloids Structural Classification other families Classification of Application Fields Source classification Plants Disease Research Fields Indole Alkaloids Cancer	Glucosidase
Castanospermine is a natural alkaloid that can be extracted from black beans or the Moreton Bay chestnut tree (Castanospermum australae). Castanospermine is an α/ β-glucosidase inhibitor. Castanospermine has anti-inflammatory, antiviral replication and anti-metastatic effects on prostate cancer. Castanospermine can be used as an immunosuppressant to prevent transplant rejection .

HY-N2584A

Isoxanthohumol 1 Publications Verification	Infection Flavonoids Classification of Application Fields Anti-aging Humulus lupulus L. Flavonones Source classification Plants Moraceae Disease Research Fields Cancer	HSV
Isoxanthohumol is a prenylflavonoid from hops and beer. Isoxanthohumol exhibits an antiproliferative activity against several human cancer cell lines. Isoxanthohumol inhibits the development of lung metastatic foci in tumor-challenged animals. Isoxanthohumol shows an antiviral activity towards herpes viruses (HSV1 and HSV2) and bovine viral diarrhea virus (BVDV) .

HY-B0617

S-Adenosyl-L-methionine S-Adenosyl methionine; Ademetionine; AdoMet	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Neurological Disease Classification of Application Fields Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	Endogenous Metabolite Apoptosis
S-Adenosyl-L-methionine (S-Adenosyl methionine) is an orally active methyl group donor. S-Adenosyl-L-methionine is a dietary supplement with potent antidepressant effects. S-Adenosyl-L-methionine also has anti‑proliferative, pro‑apoptotic and anti‑metastatic roles in cancers. S-Adenosyl-L-methionine has the potential for, cancer, liver disease and osteoarthritis research .

HY-N2587

Irigenin	Flavonoids Iridaceae Classification of Application Fields Source classification Phenols Polyphenols Plants Belamcanda chinensis (Linn.) Redouté Disease Research Fields Isoflavones Cancer	Integrin Apoptosis
Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking α9β1 and α4β1 integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties. It sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells .

HY-W017770

S-Adenosyl-L-methionine disulfate tosylate 5+ Cited Publications Ademetionine disulfate tosylate; S-Adenosyl methionine disulfate tosylate; AdoMet disulfate tosylate	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Endogenous Metabolite Apoptosis
S-Adenosyl-L-methionine disulfate tosylate is the disulfate tosylate form of S-Adenosyl-L-methionine (HY-B0617). S-Adenosyl-L-methionine is an orally active methyl group donor. S-Adenosyl-L-methionine is a dietary supplement with potent antidepressant effects. S-Adenosyl-L-methionine also has anti‑proliferative, pro‑apoptotic and anti‑metastatic roles in cancers. S-Adenosyl-L-methionine has the potential for, cancer, liver disease and osteoarthritis research .

HY-17473

Embelin 4 Publications Verification Embelic acid; Emberine; NSC 91874	Quinones Classification of Application Fields Source classification Benzene Quinones Plants Embelia laeta (Linn.) Mez Myrsinaceae Disease Research Fields Cancer	IAP NF-κB Apoptosis Autophagy
Embelin (Embelic acid), a potent, nonpeptidic XIAP inhibitor (IC₅₀=4.1 μM), inhibits cell growth, induces apoptosis, and activates caspase-9 in prostate cancer cells with high levels of XIAP. Embelin blocks NF-kappaB signaling pathway leading to suppression of NF-kappaB-regulated antiapoptotic and metastatic gene products. Embelin also induces autophagic and apoptotic cell death in human oral squamous cell carcinoma cells .

HY-B0617B

S-Adenosyl-L-methionine (1,4-butanedisulfonate) S-Adenosyl methionine (1,4-butanedisulfonate); Ademetionine (1,4-butanedisulfonate); AdoMet (1,4-butanedisulfonate)	Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields Cancer	Endogenous Metabolite Apoptosis
S-Adenosyl-L-methionine (S-Adenosyl methionine) 1,4-butanedisulfonate is an orally active methyl group donor. S-Adenosyl-L-methionine 1,4-butanedisulfonate is a dietary supplement with potent antidepressant effects. S-Adenosyl-L-methionine 1,4-butanedisulfonate also has anti‑proliferative, pro‑apoptotic and anti‑metastatic roles in cancers. S-Adenosyl-L-methionine 1,4-butanedisulfonate has the potential for, cancer, liver disease and osteoarthritis research .

HY-15398

Vitamin D3 5+ Cited Publications Cholecalciferol; Colecalciferol	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Anti-aging Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Cancer	VD/VDR Endogenous Metabolite Bacterial
Vitamin D3 (Cholecalciferol; Colecalciferol) is a naturally occuring form of vitamin D. Vitamin D3 induces cell differentiation and prevents proliferation of cancer cells.

HY-N8380

(-)-Latifolin	Structural Classification Dalbergia hupeana Hance Source classification Phenols Polyphenols Plants Fabaceae	Apoptosis Autophagy PI3K Necroptosis
(-)-Latifolin, a flavonoid, induces apoptotic cell death by targeting PI3K/AKT/mTOR/p70S6K signaling. (-)-Latifolin significantly inhibits the cell proliferation of oral squamous cell carcinoma (OSCC), and causes the anti-metastatic activities by effectively blocking cell migration, invasion, and adhesion via the inactivation of FAK/Src. (-)-Latifolin suppresses autophagic-related proteins and autophagosome formation. (-)-Latifolin inhibits necroptosis by dephosphorylating necroptosis-regulatory proteins (RIP1, RIP3, and MLKL). (-)-Latifolin has beneficial effects on anti-aging, anti-carcinogenic, anti-inflammatory, and cardio-protective activities .

Species:	Human (5) Mouse (1)
Tag:	His (5) SUMO (1) Fc (1)
Source:	HEK293 (2) E. coli Cell-free (2) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P71084

	S100A4 Protein, Mouse (His) Protein S100-A4; Metastasin; metastatic cell protein; PEL98; Placental calcium-binding protein; Protein 18A2; Protein Mts1; S100 calcium-binding protein A4; S100a4; Capl; Mts1	Mouse	E. coli
	The S100A4 protein, a calcium-binding protein, regulates cellular processes including motility, angiogenesis, differentiation, apoptosis, and autophagy. It interacts with MYH9 to enhance cell motility and chemotaxis. It modulates TP53 to reduce protein levels and stimulates cytokine production. S100A4 forms homodimers and interacts with PPFIBP1, ANXA2, TP53, CCR5, CXCR3, and FCGR3A, inhibiting FCGR3A phosphorylation. S100A4 Protein, Mouse (His) is the recombinant mouse-derived S100A4 protein, expressed by E. coli , with C-6*His labeled tag. The total length of S100A4 Protein, Mouse (His) is 101 a.a., with molecular weight of ~13.0 kDa.

HY-P70759

	HER2/CD340 Protein, Human (630a.a, HEK293, Fc) Receptor tyrosine-protein kinase erbB-2; metastatic lymph node gene 19 protein; Proto-oncogene Neu; Tyrosine kinase-type cell surface receptor HER2; ERBB2; MLN19; NGL; TKR1	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (630a.a, HEK293, Fc) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of HER2/CD340 Protein, Human (630a.a, HEK293, Fc) is 630 a.a., with molecular weight of 120-145 kDa.

HY-P70254

	HER2/CD340 Protein, Human (630a.a, HEK293, His) rHuReceptor tyrosine-protein kinase erbB-2/HER2, His; Receptor tyrosine-protein kinase erbB-2; metastatic lymph node gene 19 protein; Proto-oncogene Neu; Tyrosine kinase-type cell surface receptor HER2; ERBB2; MLN19; NGL; TKR1	Human	HEK293
	The HER2/CD340 protein is a dynamic tyrosine kinase that is essential in the neuregulin receptor complex and regulates microtubule dynamics. Upon activation, it triggers the MEMO1-RHOA-DIAPH1 pathway, inhibits GSK3B and promotes the association of APC and CLASP2 on the cell membrane to achieve microtubule stabilization. HER2/CD340 Protein, Human (630a.a, HEK293, His) is the recombinant human-derived HER2/CD340 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of HER2/CD340 Protein, Human (630a.a, HEK293, His) is 630 a.a., with molecular weight of 88-120 kDa.

HY-P702451

	STEAP2 Protein, Human (Cell-Free, His) Metalloreductase STEAP2; Prostate cancer-associated protein 1; Protein up-regulated in metastatic prostate cancer; PUMPCn; Six-transmembrane epithelial antigen of prostate 2; SixTransMembrane protein of prostate 1	Human	E. coli Cell-free
	The integral membrane protein, STEAP2, acts as an NADPH-dependent ferric-chelate reductase, facilitating transmembrane electron transfer. It employs NADPH to reduce Fe(3+) chelate, involving sequential electron transfer from NADPH to FAD and then to heme. STEAP2 also demonstrates the ability to reduce Cu(2+) to Cu(1+), showcasing its versatility in transmembrane electron transfer processes. STEAP2 Protein, Human (Cell-Free, His) is the recombinant human-derived STEAP2 protein, expressed by E. coli Cell-free , with N-10*His labeled tag. The total length of STEAP2 Protein, Human (Cell-Free, His) is 490 a.a., with molecular weight of 57.6 kDa.

HY-P702452

	STEAP2 Protein, Human (Cell-Free, His, SUMO) Metalloreductase STEAP2; Prostate cancer-associated protein 1; Protein up-regulated in metastatic prostate cancer; PUMPCn; Six-transmembrane epithelial antigen of prostate 2; SixTransMembrane protein of prostate 1	Human	E. coli Cell-free
	The integral membrane protein, STEAP2, acts as an NADPH-dependent ferric-chelate reductase, facilitating transmembrane electron transfer. It employs NADPH to reduce Fe(3+) chelate, involving sequential electron transfer from NADPH to FAD and then to heme. STEAP2 also demonstrates the ability to reduce Cu(2+) to Cu(1+), showcasing its versatility in transmembrane electron transfer processes. STEAP2 Protein, Human (Cell-Free, His, SUMO) is the recombinant human-derived STEAP2 protein, expressed by E. coli Cell-free , with N-10*His, N-SUMO labeled tag. The total length of STEAP2 Protein, Human (Cell-Free, His, SUMO) is 490 a.a., with molecular weight of 74.6 kDa.

HY-P70299

	NME1/NDPKA Protein, Human (His) rHuNucleoside diphosphate kinase A/NDPKA, His; Nucleoside Diphosphate Kinase A; NDK A; NDP Kinase A; Granzyme A-Activated DNase; GAAD; Metastasis Inhibition Factor nm23; Tumor metastatic Process-Associated Protein; nm23-H1; NME1; NDPKA; NM23	Human	E. coli
	The NME1/NDPKA protein plays a crucial role in the synthesis of nucleoside triphosphates and exhibits multiple activities, including nucleoside diphosphate kinase, serine/threonine-specific protein kinase, geranyl and farnesyl pyrophosphate kinase, histidine protein kinase and 3'-5' exonuclease functions. NME1/NDPKA Protein, Human (His) is the recombinant human-derived NME1/NDPKA protein, expressed by E. coli , with N-6*His labeled tag. The total length of NME1/NDPKA Protein, Human (His) is 152 a.a., with molecular weight of ~20.0 kDa.

Cat. No.	Product Name	Chemical Structure

HY-13702S

Nilutamide-d6
Nilutamide-d₆ (Nilandron-d6) is the deuterium labeled Nilutamide. Nilutamide (Nilandron) is a non-steroidal anti-androgen agent proposed in the research of metastatic prostatic carcinoma[1][2].

HY-13342AS

Apatinib-d8 free base

Apatinib-d₈ (free base) is the deuterium labeled Apatinib free base[1]. Apatinib free base (YN968D1 free base) is an orally bioavailable tyrosine kinase inhibitor, which selectively targets VEGFR-2 (IC50=1 nM). Apatinib free base (YN968D1 free base) is an anti-angiogenic drug for the research of advanced or metastatic gastric cancer. Apatinib free base (YN968D1 free base) potently inhibits Ret, c-Kit and c-Src with IC50s of 13, 429 and 530 nM, respectively. It also inhibits cellular phosphorylation of VEGFR-2, c-kit and PDGFRβ[2][3][4].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks